Is ASTH diluting shareholders?

Read three numbers together: shares outstanding over time (55.7M as of 2026-08-03), warrants that can convert into new shares (0 reported), and how much cash runway remains. A company short on cash with live registrations is structurally likely to issue shares.

Where do these numbers come from?

SEC EDGAR only: the XBRL company-facts API for shares, warrants and cash, and filing metadata for registrations and pricings. Every figure shows its source form, and nothing here is estimated by us beyond the arithmetic stated next to it.

Why might a warrant tranche be missing from the table?

The tranche table is built from the dimensions the company tagged in its own 10-Q or 10-K XBRL. A tranche the filer chose not to dimension does not appear, and its absence proves nothing: the exhibits remain the ground truth. Everything shown carries the filing it came from.

Dilution profile // every instrument, one screen, from SEC filings

Astrana Health, Inc. (ASTH)

CIK 1083446 · all EDGAR filings →

Overall dilution risk

HIGHworst of 4 computed signals (offering ability)

= the worst band among the computed sub-ratings, no hidden weighting

Offering ability

HIGH$121M registered

= total registered offering amount from the fee exhibits of live registrations (bands: $1M / $20M)

one or more live registrations had no structured fee data, so the true total is AT LEAST this

Overhead supply

LOWwarrants = 0% of O/S

= warrant shares outstanding divided by current shares outstanding (bands: 20% / 50%)

warrants only; converts, ATMs and equity lines are not in free structured data, so the true overhead is AT LEAST this

Historical dilution

LOW-4% O/S in 3y

= share count now vs 3 years ago (bands: 30% / 100%); a reverse split pushes this negative

a reverse-split-sized cliff is in this window; read the chart

Cash need

LOWoperating cash flow positive

= cash vs trailing operating burn (bands: 6mo / 24mo; positive operating CF = low)

Same rating bands the category standard uses, but free, with the formula on the chip and the gaps in the data said out loud.

Shares outstanding over time

Latest: 55.7M shares as of Aug 3, 2026 (10-Q). Share count fell from 48.6M to 4.9M between Feb 13, 2015 and Jul 8, 2015, a pattern consistent with a reverse split (roughly 1-for-10); simultaneous issuance can skew the raw ratio, so confirm in the filings. The red bar marks the cliff.

Cash runway

Self-funding

profitable · generates cash

Full breakdown: cash runway tool · source filing →

Warrants

Warrants outstanding: 0 underlying shares, as reported Dec 31, 2023 (10-K).

Reported exercise price: $9.93 (aggregate figure as tagged; individual tranches vary).

Balance-sheet fair value of warrants: $50,937 as of Oct 31, 2013.

Rough fully diluted estimate: 55.7M = 55.7M O/S + 0 warrant shares. An estimate, not a filing figure: it ignores converts, options and RSUs, and the two inputs carry different as-of dates.

Convertible notes

No convertible-note facts tagged in the 10-Q filed Aug 10, 2026. If convertible notes exist, their terms live in exhibit prose for this filer and are not parsed; absence of a tag is not proof of absence. The exhibits are the ground truth.

Fully diluted build-up

Shares outstanding plus every potential-share instrument the filer tagged in XBRL, each at its own as-of date. An estimate assembled from filed figures, not a filing figure itself.

Shares outstanding	55.7M	Aug 3, 2026
+ Warrants (aggregate, as tagged) (if exercised)	0	Dec 31, 2023
Fully diluted estimate	55.7M	+0.0% vs O/S

Still excluded, because the filer does not tag them in countable form: employee options and RSUs, any instrument living only in exhibit prose, and instruments above missing a share count. Inputs carry different as-of dates, shown per row. Each figure traces to the tranche and note tables above and their cited filings.

Registrations and offerings

Registered offering capacity on live registrations: $120.8Mfrom the structured fee exhibits; registered is not remaining, takedowns are not subtracted

S-3ASRMar 31, 2026fee exhibit found but no total offering amount (fees deferred, typical for automatic shelves)filing →

S-3ASRMar 31, 2026$120.8M registeredfiling →

S-3ASRAug 16, 2023no structured fee exhibit in this filing (predates fee-data XBRL or fee deferred)filing →

Last 12 months: 0 executed · 2 registered.

REGISTEREDMar 31, 2026Automatic shelf registration — effective immediately (large filers)S-3ASR →

UPDATEJul 15, 2024Resale prospectus — existing holders registering to sell424B7 →

EXECUTEDFeb 2, 2024Unregistered share sale disclosed (8-K item 3.02)8-K →

REGISTEREDAug 16, 2023Automatic shelf registration — effective immediately (large filers)S-3ASR →

EXECUTEDSep 12, 2019Unregistered share sale disclosed (8-K item 3.02)8-K →

EXECUTEDAug 29, 2019Unregistered share sale disclosed (8-K item 3.02)8-K →

EXECUTEDMay 13, 2019Unregistered share sale disclosed (8-K item 3.02)8-K →

EFFECTIVEMay 13, 2019SEC declared a registration effective — selling can beginEFFECT →

REGISTEREDApr 29, 2019S-3 registration — capacity to sell shares, not a sale yetS-3 →

UPDATEMar 8, 2019Prospectus update — often a resale registration, not necessarily new capital424B3 →

Full history and shelf status: offering checker · S-3 shelf checker

Source: SEC EDGAR XBRL company facts and filing metadata, fetched live and cached briefly. Share counts are cover-page figures with their form named. Warrant tranches and convertible notes come from the dimensioned facts in the latest 10-Q/10-K instance document, exactly as the company tagged them; untagged tranches and notes are absent, not disproven. Nothing on this page is manually verified and nothing is behind a login: what free data supports is shown, what it cannot support is stated. Not investment advice.

Keep going: float checker · offering calendar · short-squeeze screener · full ASTH workspace